<p>Protara Therapeutics, Inc.（納斯達克代碼：TARA - 免費報告）- HC Wainwright 在 11 月 24 日星期一發布的報告中上調了 Protara Therapeutics 2025 年第四季度每股收益（EPS）預期。HC Wainwright 分析師 A. Maldonado 現在預計該公司本季度每股收益為（$0.32），高於之前預測的（$0.36）。HC Wainwright 對該股票給予 “買入” 評級，目標價為$23.00。Protara Therapeutics 當前全年的共識收益預期為每股（$3.32）。HC Wainwright 還發布了 Protara Therapeutics 2026 年第一季度每股收益預期為（$0.33），2026 財年每股收益預期為（$1.37），2027 財年每股收益預期為（$1.70），2028 財年每股收益預期為（$0.95）以及 2029 財年每股收益預期為（$0.34）。</p>
<p>另外，Weiss Ratings 在 10 月 8 日星期三的報告中重新發布了 Protara Therapeutics 的 “賣出（d-）” 評級。一位分析師對該股票給予了強烈買入評級，五位分析師給予了買入評級，還有一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，Protara Therapeutics 的平均評級為 “適度買入”，共識目標價為$19.60。</p>
<p>獲取 <strong>Protara Therapeutics</strong> 警報：</p>
<p><strong>獲取我們對 TARA 的最新分析</strong></p>
<h2>Protara Therapeutics 股價上漲 2.6%</h2>
<p>TARA 股票在星期三開盤價為$7.56。該公司的 50 日移動平均線為$5.07，200 日移動平均線為$3.82。該股票的市值為$2.9172 億，市盈率為-4.67，貝塔值為 1.59。Protara Therapeutics 的 1 年最低價為$2.48，1 年最高價為$10.48。</p>
<p>Protara Therapeutics（納斯達克代碼：TARA - 獲取免費報告）最近一次發佈財報是在 11 月 10 日星期一。該公司報告本季度每股收益為（$0.31），超出共識預期的（$0.39）$0.08。</p>
<h2>Protara Therapeutics 的機構交易</h2>
<p>一些機構投資者最近對該股票的持倉進行了調整。洛杉磯資本管理公司在第二季度購買了 Protara Therapeutics 的新股份，價值$47,000。Velan Capital Investment Management LP 在第一季度增加了對 Protara Therapeutics 的持倉，增幅為 5.6%。Velan Capital Investment Management LP 現在擁有 1,667,800 股該公司的股票，價值$7,105,000，在此期間又收購了 88,800 股。Walleye Capital LLC 在第一季度將其在 Protara Therapeutics 的股份提高了 3.9%。Walleye Capital LLC 現在擁有 229,454 股該公司的股票，價值$977,000，在上個季度又收購了 8,640 股。查爾斯·施瓦布投資管理公司在第一季度購買了 Protara Therapeutics 的新股份，價值約$64,000。最後，美國世紀公司在第一季度購買了 Protara Therapeutics 的新股份，價值約$154,000。對沖基金和其他機構投資者持有該公司 38.13% 的股份。</p>
<h2>關於 Protara Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Protara Therapeutics, Inc.是一家臨牀階段的生物製藥公司，致力於推進用於治療癌症和罕見疾病的變革性療法。該公司的主導項目是 TARA-002，一種正在進行的細胞療法，目前處於針對非肌肉侵襲性膀胱癌和淋巴畸形的二期臨牀試驗中。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票比 Protara Therapeutics 更好</li>
<li>什麼是財報？</li>
<li>歷史表明這三隻股票適合在 12 月購買</li>
<li>高分紅 REIT：它們是理想的多元化方式嗎？</li>
<li>華納兄弟出售傳聞升温：投資者需要知道什麼</li>
<li>三隻小盤股具有巨大的回報潛力</li>
<li>從科學項目到溶劑：WeRide 的 761% 收入激增</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSQQ"/></p>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Protara Therapeutics 嗎？</h2>
<p>在考慮 Protara Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Protara Therapeutics 並不在名單上。</p>
<p>雖然 Protara Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TARA

<p>HC Wainwright 已經上調了 Protara Therapeutics 2025 年第四季度每股收益（EPS）的預期，現在預計為每股（$0.32），之前為（$0.36）。該公司維持 “買入” 評級，目標價為 $23.00。Protara 的股票開盤價為 $7.56，市值為 $2.9172 億。分析師對其給予 “適度買入” 評級，但 Weiss Ratings 則發佈了 “賣出” 評級。機構投資者持有該股票的 38.13%。Protara 正在推進癌症和罕見疾病的治療，主要項目 TARA-002 正在進行第二階段臨牀試驗</p>

<p>Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - HC Wainwright upped their Q4 2025 earnings per share (EPS) estimates for shares of Protara Therapeutics in a report released on Monday, November 24th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.32) for the quarter, up from their previous forecast of ($0.36). HC Wainwright has a &#34;Buy&#34; rating and a $23.00 price objective on the stock. The consensus estimate for Protara Therapeutics' current full-year earnings is ($3.32) per share. HC Wainwright also issued estimates for Protara Therapeutics' Q1 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.70) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at ($0.34) EPS.</p>
<div class="lb-trans"><p>Protara Therapeutics, Inc.（納斯達克代碼：TARA - 免費報告）- HC Wainwright 在 11 月 24 日星期一發布的報告中上調了 Protara Therapeutics 2025 年第四季度每股收益（EPS）預期。HC Wainwright 分析師 A. Maldonado 現在預計該公司本季度每股收益為（$0.32），高於之前預測的（$0.36）。HC Wainwright 對該股票給予 “買入” 評級，目標價為$23.00。Protara Therapeutics 當前全年的共識收益預期為每股（$3.32）。HC Wainwright 還發布了 Protara Therapeutics 2026 年第一季度每股收益預期為（$0.33），2026 財年每股收益預期為（$1.37），2027 財年每股收益預期為（$1.70），2028 財年每股收益預期為（$0.95）以及 2029 財年每股收益預期為（$0.34）。</p>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Protara Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Protara Therapeutics has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $19.60.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日星期三的報告中重新發布了 Protara Therapeutics 的 “賣出（d-）” 評級。一位分析師對該股票給予了強烈買入評級，五位分析師給予了買入評級，還有一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，Protara Therapeutics 的平均評級為 “適度買入”，共識目標價為$19.60。</p>
</div><p>Get <strong>Protara Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Protara Therapeutics</strong> 警報：</p>
</div><p><strong>Get Our Latest Analysis on TARA</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 TARA 的最新分析</strong></p>
</div><h2>Protara Therapeutics Trading Up 2.6%</h2>
<div class="lb-trans"><h2>Protara Therapeutics 股價上漲 2.6%</h2>
</div><p>TARA stock opened at $7.56 on Wednesday. The company's 50 day moving average is $5.07 and its 200 day moving average is $3.82. The stock has a market cap of $291.72 million, a price-to-earnings ratio of -4.67 and a beta of 1.59. Protara Therapeutics has a 1-year low of $2.48 and a 1-year high of $10.48.</p>
<div class="lb-trans"><p>TARA 股票在星期三開盤價為$7.56。該公司的 50 日移動平均線為$5.07，200 日移動平均線為$3.82。該股票的市值為$2.9172 億，市盈率為-4.67，貝塔值為 1.59。Protara Therapeutics 的 1 年最低價為$2.48，1 年最高價為$10.48。</p>
</div><p>Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.08.</p>
<div class="lb-trans"><p>Protara Therapeutics（納斯達克代碼：TARA - 獲取免費報告）最近一次發佈財報是在 11 月 10 日星期一。該公司報告本季度每股收益為（$0.31），超出共識預期的（$0.39）$0.08。</p>
</div><h2>Institutional Trading of Protara Therapeutics</h2>
<div class="lb-trans"><h2>Protara Therapeutics 的機構交易</h2>
</div><p>A number of institutional investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC bought a new stake in Protara Therapeutics during the 2nd quarter valued at $47,000. Velan Capital Investment Management LP increased its position in shares of Protara Therapeutics by 5.6% in the first quarter. Velan Capital Investment Management LP now owns 1,667,800 shares of the company's stock valued at $7,105,000 after acquiring an additional 88,800 shares during the period. Walleye Capital LLC raised its stake in shares of Protara Therapeutics by 3.9% during the first quarter. Walleye Capital LLC now owns 229,454 shares of the company's stock valued at $977,000 after acquiring an additional 8,640 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Protara Therapeutics during the first quarter worth about $64,000. Finally, American Century Companies Inc. bought a new stake in shares of Protara Therapeutics in the first quarter worth about $154,000. Hedge funds and other institutional investors own 38.13% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者最近對該股票的持倉進行了調整。洛杉磯資本管理公司在第二季度購買了 Protara Therapeutics 的新股份，價值$47,000。Velan Capital Investment Management LP 在第一季度增加了對 Protara Therapeutics 的持倉，增幅為 5.6%。Velan Capital Investment Management LP 現在擁有 1,667,800 股該公司的股票，價值$7,105,000，在此期間又收購了 88,800 股。Walleye Capital LLC 在第一季度將其在 Protara Therapeutics 的股份提高了 3.9%。Walleye Capital LLC 現在擁有 229,454 股該公司的股票，價值$977,000，在上個季度又收購了 8,640 股。查爾斯·施瓦布投資管理公司在第一季度購買了 Protara Therapeutics 的新股份，價值約$64,000。最後，美國世紀公司在第一季度購買了 Protara Therapeutics 的新股份，價值約$154,000。對沖基金和其他機構投資者持有該公司 38.13% 的股份。</p>
</div><h2>About Protara Therapeutics</h2>
<div class="lb-trans"><h2>關於 Protara Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.</p>
<div class="lb-trans"><p>Protara Therapeutics, Inc.是一家臨牀階段的生物製藥公司，致力於推進用於治療癌症和罕見疾病的變革性療法。該公司的主導項目是 TARA-002，一種正在進行的細胞療法，目前處於針對非肌肉侵襲性膀胱癌和淋巴畸形的二期臨牀試驗中。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Protara Therapeutics</li>
<li>What Are Earnings Reports?</li>
<li>History Says These are 3 Stocks to Buy for December</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Warner Bros. Sale Rumors Heat Up: What Investors Need to Know</li>
<li>3 Small Caps With Big Return Potential</li>
<li>From Science Project to Solvent: WeRide’s 761% Revenue Surge</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 Protara Therapeutics 更好</li>
<li>什麼是財報？</li>
<li>歷史表明這三隻股票適合在 12 月購買</li>
<li>高分紅 REIT：它們是理想的多元化方式嗎？</li>
<li>華納兄弟出售傳聞升温：投資者需要知道什麼</li>
<li>三隻小盤股具有巨大的回報潛力</li>
<li>從科學項目到溶劑：WeRide 的 761% 收入激增</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=TARA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Protara Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Protara Therapeutics 嗎？</h2>
</div><p>Before you consider Protara Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Protara Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Protara Therapeutics 並不在名單上。</p>
</div><p>While Protara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Protara Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 對 TARA 第四季度的盈利持積極態度